Table 1.
Clinicopathological characteristics of individuals examined in this study.
| All cases (n = 162) | Cases analyzed by 2DICAL (n = 40) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PCa*(n = 54) | BPH (n = 22) |
Prostatitis (n = 6) |
RCC (n = 20) |
Healthy (n = 60) |
P value | PCa* (n = 25) | Healthy (n = 15) |
P value | ||
| Age | (mean ± SD) | 66. 3 ± 7.3 | 72.3 ± 7.5 | 65.8 ± 5.9 | 63.8 ± 8.5 | 67.2 ± 8.8 | 0.544**** | 67.0 ± 7.2 | 65.1 ± 8.0 | 0.440**** |
|
| ||||||||||
| Stage |
I | 0 | 0 | |||||||
| II | 50 | 22 | ||||||||
| III | 2 | 2 | ||||||||
| IV | 2 | 1 | ||||||||
|
| ||||||||||
| TNM classification** |
||||||||||
| T1cN0M0 | 25 | 10 | ||||||||
| T2aN0M0 | 15 | 7 | ||||||||
| T2bN0M0 | 2 | 1 | ||||||||
| T2cN0M0 | 8 | 4 | ||||||||
| T3aN0M0 | 2 | 2 | ||||||||
| T4N0M1b | 1 | 1 | ||||||||
| T4N1M1b | 1 | 0 | ||||||||
|
| ||||||||||
| PSA*** | ng/mL | |||||||||
| <4 | 2 | 11 | 4 | 51 | 2 | 12 | ||||
| 4≦, ≦10 | 30 | 10 | 2 | 9 | <0.001***** | 14 | 3 | <0.001***** | ||
| 10< | 22 | 1 | 0 | 0 | 9 | 0 | ||||
|
| ||||||||||
| Gleason score |
||||||||||
| 5 | 2 | 1 | ||||||||
| 6 | 15 | 7 | ||||||||
| 7 | 25 | 12 | ||||||||
| 8 | 8 | 4 | ||||||||
| 9 | 2 | 1 | ||||||||
| 10 | 2 | 0 | ||||||||
*Abbreviation: PCa: prostate cancer; **according to TNM Classification of Malignant Tumors (International Union Against Cancer), 6th Edition; ***measured by Tandem R kit before the first treatment; ****Welch's t-test; *****Fisher's exact test.